tradingkey.logo

Amgen Says Maritide Shows About 20% Weight Loss In Obesity Without T2d

ReutersJun 23, 2025 6:44 PM

- Amgen Inc AMGN.O:

  • RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS

  • AMGEN - IN PEOPLE LIVING WITH OBESITY WITH TYPE 2 DIABETES, MARITIDE DEMONSTRATED UP TO ABOUT 17% AVERAGE WEIGHT LOSS AND ROBUST HBA1C IMPROVEMENTS

  • AMGEN INC - MARITIDE SHOWS ABOUT 20% WEIGHT LOSS IN OBESITY WITHOUT T2D

  • AMGEN INC - MARITIME PHASE 3 CHRONIC WEIGHT MANAGEMENT STUDIES ARE ACTIVELY ENROLLING

  • AMGEN- PHASE 3 STUDIES IN PEOPLE LIVING WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, HEART FAILURE AND OBSTRUCTIVE SLEEP APNEA TO BE INITIATED IN 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI